Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial)

被引：0
作者：
Osamu Shimomura
Masato Endo
Hirokazu Makishima
Takeshi Yamada
Shinji Hashimoto
Haruko Numajiri
Yoshihiro Miyazaki
Manami Doi
Kinji Furuya
Kazuhiro Takahashi
Toshikazu Moriwaki
Naoyuki Hasegawa
Yoshiyuki Yamamoto
Yusuke Niisato
Mariko Kobayashi
Masashi Mizumoto
Kei Nakai
Takashi Saito
Sodai Hoshiai
Tsukasa Saida
Bryan J. Mathis
Kensaku Mori
Takahito Nakajima
Kiichiro Tsuchiya
Hideyuki Sakurai
Tatsuya Oda
机构：
[1] University of Tsukuba,Department of Gastrointestinal and Hepato
[2] University of Tsukuba,Biliary
[3] University of Tsukuba,Pancreatic Surgery, Faculty of Medicine
[4] University of Tsukuba,Department of Gastroenterology
[5] University of Tsukuba Hospital,Department of Radiation oncology
来源：
BMC Cancer | / 23卷
关键词：
Locally advanced pancreatic cancer; Clinical trial; Multidisciplinary treatment; Proton beam therapy; Hyperthermia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 10 条
  • [1] Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial)
    Shimomura, Osamu
    Endo, Masato
    Makishima, Hirokazu
    Yamada, Takeshi
    Hashimoto, Shinji
    Numajiri, Haruko
    Miyazaki, Yoshihiro
    Doi, Manami
    Furuya, Kinji
    Takahashi, Kazuhiro
    Moriwaki, Toshikazu
    Hasegawa, Naoyuki
    Yamamoto, Yoshiyuki
    Niisato, Yusuke
    Kobayashi, Mariko
    Mizumoto, Masashi
    Nakai, Kei
    Saito, Takashi
    Hoshiai, Sodai
    Saida, Tsukasa
    Mathis, Bryan J.
    Mori, Kensaku
    Nakajima, Takahito
    Tsuchiya, Kiichiro
    Sakurai, Hideyuki
    Oda, Tatsuya
    BMC CANCER, 2023, 23 (01)
  • [2] Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Borad, Mitesh J.
    Laheru, Daniel A.
    Smith, Lon S.
    Wood, Tina E.
    Korn, Ronald L.
    Desai, Neil
    Trieu, Vuong
    Iglesias, Jose L.
    Zhang, Hui
    Soon-Shiong, Patrick
    Shi, Tao
    Rajeshkumar, N. V.
    Maitra, Anirban
    Hidalgo, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (34) : 4548 - 4554
  • [3] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [4] Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naive Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
    Gong, Jun
    Osipov, Arsen
    Lorber, Jeremy
    Tighiouart, Mourad
    Kwan, Albert K.
    Muranaka, Hayato
    Akinsola, Rasaq
    Billet, Sandrine
    Levi, Abrahm
    Abbas, Anser
    Davelaar, John
    Bhowmick, Neil
    Hendifar, Andrew E.
    BIOMEDICINES, 2023, 11 (05)
  • [5] A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)
    Ozaka, Masato
    Nakachi, Kohei
    Kobayashi, Satoshi
    Ohba, Akihiro
    Imaoka, Hiroshi
    Terashima, Takeshi
    Ishii, Hiroshi
    Mizusawa, Junki
    Katayama, Hiroshi
    Kataoka, Tomoko
    Okusaka, Takuji
    Ikeda, Masafumi
    Sasahira, Naoki
    Miwa, Haruo
    Mizukoshi, Eishiro
    Okano, Naohiro
    Mizuno, Nobumasa
    Yamamoto, Tomohisa
    Komatsu, Yoshito
    Todaka, Akiko
    Kamata, Ken
    Furukawa, Masayuki
    Fujimori, Nao
    Katanuma, Akio
    Takayama, Yukiko
    Tsumura, Hidetaka
    Fukuda, Haruhiko
    Ueno, Makoto
    Furuse, Junji
    EUROPEAN JOURNAL OF CANCER, 2023, 181 : 135 - 144
  • [6] Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
    Jameson, Gayle S.
    Hosein, Peter J.
    Pierce, Erin
    Kamgar, Mandana
    Gordon, Michael S.
    Snyder, Courtney
    Roe, Denise J.
    Wertheim, Betsy C.
    Davey, Marina
    Barrett, Michael T.
    Von Hoff, Daniel D.
    Borazanci, Erkut
    CANCER MEDICINE, 2024, 13 (12):
  • [7] Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407)
    Mizusawa, Junki
    Fukutomi, Akira
    Katayama, Hiroshi
    Ishii, Hiroshi
    Ioka, Tatsuya
    Okusaka, Takuji
    Ueno, Hideki
    Ueno, Makoto
    Ikeda, Masafumi
    Mizuno, Nobumasa
    Ozaka, Masato
    Fukuda, Haruhiko
    Furuse, Junji
    PANCREATOLOGY, 2018, 18 (07) : 841 - 845
  • [8] Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
    Christelle Bouchart
    Julie Navez
    Ivan Borbath
    Karen Geboes
    Timon Vandamme
    Jean Closset
    Luigi Moretti
    Pieter Demetter
    Marianne Paesmans
    Jean-Luc Van Laethem
    BMC Cancer, 23 (1)
  • [9] Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel plus /- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial
    Bouchart, Christelle
    Navez, Julie
    Borbath, Ivan
    Geboes, Karen
    Vandamme, Timon
    Closset, Jean
    Moretti, Luigi
    Demetter, Pieter
    Paesmans, Marianne
    Van Laethem, Jean-Luc
    BMC CANCER, 2023, 23 (01)
  • [10] Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicentre, single-arm, phase II trial (ICSBR) protocol
    Zhang, Chenyan
    Yang, Heqi
    Chang, Chen
    Li, Ruizhen
    Xiong, Junjie
    Kang, Deying
    He, Du
    Liu, Xi-Jiao
    Cheng, Ke
    Cao, Dan
    BMJ OPEN, 2024, 14 (07): : 1 - 8
1